InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs ...Middle East

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit®...

Hence then, the article about inxmed enters license agreement with escugen to develop next generation adcs was published today ( Wednesday 20/12/2023 - 04:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs )

Also on site :

• U.K. Music Tech Firms Face Growth Investment Crisis, “AI Raises Stakes for Gov’t Action,” Study Warns
• The Case for Returning U.S. Public Lands to Indigenous People
• How Lebanon’s Best Chance to Disarm Hezbollah Failed